Gathered together on our panel are a group of technology and business experts who will help decipher the issues that make up this complex topic.Join our #Tweetchat on “Virtual Clinical Trials: Clinical Innovation and Enterprise Adoption”. Tune in on 24th Feb | 11 AM EDT https://t.co/lXfl9BHwhG #OneHCL #STinsights@ArifurDeepu @TheTylerPugsley @DonnaKLencki @IrmaRaste @Haider_Alleg @Robinff3 @WearablesExpert @AdiGaskell pic.twitter.com/sAZeLGPtN2
— CIO Straight Talk (@CIOStraightTalk) February 24, 2021
We begin by getting their insights on how a distributed and decentralized IT system will effect the pharma R&D pipeline.Just 30 minutes to go for #Tweetchat on “Virtual Clinical Trials: Clinical Innovation and Enterprise Adoption” with an amazing panel. Visit https://t.co/16ERZxIgDz to join the discussion. #OneHCL #STinsights pic.twitter.com/QMjxOj54hd
— CIO Straight Talk (@CIOStraightTalk) February 24, 2021
New challenges are leading to greater acceleration in technology adoption, and clinical trials are no different.We are going live with the #Tweetchat. Here's the 1st question. #STinsights #OneHCL pic.twitter.com/6Q80yWfOlh
— CIO Straight Talk (@CIOStraightTalk) February 24, 2021
A1
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
We’re already seeing a major shift in healthcare delivery to the patient’s home, IV medications, annual physicals, even Urgent Care.
Clinical trials are no exception to this trend.
@CIOStraightTalk #OneHCL #STinsights #clinicaltrials
Couldn't agree more here, Robin. We're already seeing so much acceleration with #digitalhealth - VCTs are no different. @CIOStraightTalk #OneHCL #STinsights #clinicaltrials
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
Agreed!
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
From the patient's point of view, clinical trial treatments are no different than normal treatments - both treat the patient's disease@CIOStraightTalk #OneHCL #STinsights #clinicaltrials #tweetchat
#stinsights also having a bit of science back to the topic is welcome. What covid brought is a lot of noise and empirical conversations went south quickly
— Haider Alleg (@Haider_Alleg) February 24, 2021
A1a: VCTs are here now. The pandemic helped push VCTs into the mainstream for more sponsors, but the value of VCTs are real w/benefits in recruitment/retention, data quality, study cost and most importantly SPEED @CIOStraightTalk #STInsights #OneHCL
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
The pandemic accelerated the adoption of telemedicine, remote consent, direct to patient drugs/labs, eCOA, & ePRO. The transformative value for the ecosystem will continue into the future for Pharma R&D see here: https://t.co/FuCgfVf9Ha @CIOStraightTalk #STInsights #OneHCL
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
I always say transformation = adoption x scalability
— Haider Alleg (@Haider_Alleg) February 24, 2021
Network effects too
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
Hey Tyler good seeing you here yes and the keyword is rebuilding an ecosystem that can make sense in a multichannel world a bit like the Fintech ecosystem brought to banking
— Haider Alleg (@Haider_Alleg) February 24, 2021
Great seeing you too! Agree 💯
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
Great point! @TheTylerPugsley How can we control unintended consequences that can occur as a result of increased patient access to and ownership of their health data? #STinsights #OneHCL @AdiGaskell @IrmaRaste @WearablesExpert @Robinff3 @ArifurDeepu @DonnaKLencki @Haider_Alleg https://t.co/IxJn9IKf5D
— Aayu Bajaj (@aayu_bajaj) February 24, 2021
I'm reminded that Lee Hood thought by 2016 we'd all have our medical data on a card that we could plug into any interaction with the medical fraternity. We have a bit of ground to make up.
— Adi Gaskell (@AdiGaskell) February 24, 2021
That’s why I believe we need a framework to transport these data at a global level ans not waiting for local regulators to align. The EU is showing some will to go that way but it is slow
— Haider Alleg (@Haider_Alleg) February 24, 2021
It's all very bitty and fragmented at the moment. There's no real ARPANET equivalent working on something that could spread across the world
— Adi Gaskell (@AdiGaskell) February 24, 2021
#STinsights yes and here my question is who will start it... if not the regular or the industry it might be the opportunity for a whole ecosystem to do it as it happened with crypto
— Haider Alleg (@Haider_Alleg) February 24, 2021
Patients are Consumers. Open access, provide valuable insights back to patients and accelerate the development of new therapies
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#empowerment the only way to get responsibility in the system as well and here facts based decision making is key
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Q1 The need for VCT preexisted the recent pandemic situation, however, as Covid-19 impacted all clinical trials related operations, the industry is on track to adopt VCT technologies to keep studies on-time & provide added patient convenience
— Arifur Deepu (@ArifurDeepu) February 24, 2021
Obviously collecting data in traditional settings has been harder during Covid and virtual trials solved that. We're already seeing regulations emerge to support virtual trials and 1000s of trials are done this way now @CIOStraightTalk #STinsights #OneHCL pic.twitter.com/7TOImfVcXY
— Adi Gaskell (@AdiGaskell) February 24, 2021
It’s all about the definitions.
— Craig Lipset (@CraigLipset) February 25, 2021
Some of the market research / forecasts have a tremendous amount of “non-DCT” bloat embedded in their figures.
They are directionally correct, but the absolute numbers on these forecasts are often questionable.
Yes, that's undoubtedly true. They do illustrate the direction of travel, however.
— Adi Gaskell (@AdiGaskell) February 25, 2021
VCTs impact patient recruitment, saving time & money with a vast array of digital tools that can be used. Also creates new possibilities for patients to take full advantage of apps, electronic monitoring devices & social engagement platforms. @CIOStraightTalk #STinsights #OneHCL https://t.co/eUyKFBohCx
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
Completely agree Donna. Patient Recruitment drags the Clinical Trial timelines and Decentralizing the process is a key
— Arifur Deepu (@ArifurDeepu) February 24, 2021
A1: It is the future for pharma really, virtual clinical trials will be the norm going forward.
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
We need to leverage emerging technologies effectively, but also consider many other aspects, such as patient engagement. #OneHCL #CIOStraightTalk #digitalhealth #TheWearablesExpert https://t.co/GOEFh8DimP
Yes! They create new possibilities for patients to take full advantage of apps, electronic monitoring devices & social engagement platforms. @CIOStraightTalk #STinsights #OneHCL #digitalhealth
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
With my #patientadvocate hat on, I couldn’t agree more @DonnaKLencki! #patients need more options to be able to participate in #clinicaltrials. And the industry needs more diverse #patient base. #STinsights #healthtech #digitalhealth #healthcare #research https://t.co/sKzEOom4A8
— Irma Rastegayeva✨ Influence Through Storytelling ™ (@IrmaRaste) February 24, 2021
Agreed~ we can't underestimate the challenges – relatively new, regulatory framework is in early phase, field guidelines unclear, emphasis on data protection, digital recruitment may have limitations (ie. Elderly, limited access) @CIOStraightTalk #STinsights #OneHC
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
Yes, similar challenges here as with the adoption of #telehealth, including access to broadband. So #equity & digital divide concerns are there, but still virtual distributed #clinicaltrials is such a step forward! @BavassoRichie @nQ_Medical @CIOStraightTalk #STinsights #OneHC
— Irma Rastegayeva✨ Influence Through Storytelling ™ (@IrmaRaste) February 24, 2021
It's so sad how many patients at the moment are oblivious to trials existing that could really help them. I think @LillyPad released some data a few years ago suggesting just 16% of cancer patients are aware of trials they can participate in
— Adi Gaskell (@AdiGaskell) February 24, 2021
Great point here. VCTs open up accessibility~ I'd love to see more awareness of them. @CIOStraightTalk #STinsights #OneHC https://t.co/Se5D0GAMr1
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
Great point, @DonnaKLencki and @IrmaRaste. During the pandemic especially, virtual #clinicaltrials are beneficial for those patients who are unable to attend a clinic in person, either due to vulnerable health status, lack of transportation, or any other reason. https://t.co/NX7fgo823r
— Ashley A. Holmes (@AshleyAHolmes1) February 24, 2021
Yes~ this is a central theme for the most recent acceleration of VCTs. Like with other #digitalhealth, they provide flexibility and convenience. @CIOStraightTalk #STinsights #OneHC https://t.co/931JpuPUyA
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
@DonnaKLencki How will organizations deal with privacy concerns that will lead to patients becoming more protective of their data?@CIOStraightTalk #STinsights #OneHCL https://t.co/ATuqP6bGRC
— Radhika Gautam (@Radhika07194993) February 24, 2021
Definitely @Robinff3 ! With this increased ease of participation through digitization, Do you think it will meaningfully increase patient participation in clinical trials? Any trends that you have observed so far? @WearablesExpert #STinsights #OneHCL https://t.co/8pBrLawz5v
— Apoorva Agarwal (@Apoorva_Ag) February 24, 2021
ABSOLUTELY !!!!
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
In-person clinical trials are limited to their geographic vicinity - part of the reason many trials aren't filled
Virtual clinical trials expand the patient pool nationally - suddenly, millions of more patients have access@CIOStraightTalk #OneHCL #STinsights
Yes! Remote or decentralized solutions can accelerate time table and impact cost. @CIOStraightTalk #STinsights #OneHC #telemednow #telehealth https://t.co/b73lZp4uKE
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
Time and cost wins are indisputable. @CIOStraightTalk #STinsights #OneHC @nQ_Medical @BavassoRichie
— Irma Rastegayeva✨ Influence Through Storytelling ™ (@IrmaRaste) February 24, 2021
Then our panel turns their attention to specific instances in which technology has already begun to make a difference in the field.#STinsights @CIOStraightTalk #OneHCL agree. Keeping Patient Centricity in mind
— Arifur Deepu (@ArifurDeepu) February 24, 2021
New innovations are placing patients at the heart of process and mainstreaming emerging technologies at a rapid pace.Join in the conversation using #STinsights #OneHCL #Tweetchat. And our second question is: pic.twitter.com/bq3YBft4ox
— CIO Straight Talk (@CIOStraightTalk) February 24, 2021
2. A lot of the technology is helping to make trials more patient-centric. For instance, wearable technology offers an easy (if passive) form of data collection. They also make recruiting a broader sample of patients easier @CIOStraightTalk #STinsights #OneHCL
— Adi Gaskell (@AdiGaskell) February 24, 2021
Yes! Automated solutions contribute to rapid expansion, especially with electronic methods to capture #healthdata w/ #wearables and other #mhealth data. Also an increased use of #genomics data. @CIOStraightTalk #STinsights #OneHC https://t.co/m8sLIjbSfH
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
It's also important that we diversify access to trials. @universityofga showed during #COVID19 that the minorities that are most affected by the virus were least likely to participate in vaccine trials https://t.co/3bfuNfeZY5 @CIOStraightTalk #STinsights #OneHCL
— Adi Gaskell (@AdiGaskell) February 24, 2021
Thanks for sharing this article. The more diversity we have in trials, the more likely we are to find solutions that are effective and safe across all genders and racial/ethnic groups. It's crucial to see outcomes data for to gender, race, and ethnicity. #STinsights https://t.co/rOszr6jEjo
— Ashley A. Holmes (@AshleyAHolmes1) February 24, 2021
Scandalous, yet not entirely surprising
— Wayne Ellis #FBPE (@WayneEllis2) February 24, 2021
Agree Adi. Sensor enabled med devices devices and SaMD are key components of Virtualizing the patient data collection framework
— Arifur Deepu (@ArifurDeepu) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Q2 IoT (Internet of Things) led digital transformation is transforming Pharma Clinical Trials with evolving technologies such as Mobile Health Apps, Wearables, Telemedicine, AR/VR and AI driven Patient Engagement Platform
— Arifur Deepu (@ArifurDeepu) February 24, 2021
How are concerns around privacy w.r.t. these wearable being addressed?
— IamShowmock (@showmock) February 24, 2021
Shouldn’t be different as others data vehicles but here the healthcare aspects add a layer of complexity. This isn’t a tech problem anymore but a healthcare / regulatory one
— Haider Alleg (@Haider_Alleg) February 24, 2021
Exactly - we already have privacy & security figured out for medical devices - wearables are no different
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
This is a compliance & regulatory issue, not about the tech specifically #OneHCL #STinsights #clinicaltrials
Regulatory and change management. Not too long ago people thought it was weird to ride in a stranger's car or stay in their house. Now @Uber and @Airbnb are ubiquitous
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#STinsights people don’t know what they don’t know until they taste it
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STinsights the big shift though is when your decision making process as a doctor or a patient is wired with a insights assistant in the middle. This is the beginning of a A2A or application to application business model and frankly we aren’t ready for this
— Haider Alleg (@Haider_Alleg) February 24, 2021
A2: /1
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
There are a # of innovative tech helping shift clinical trials to the home.
Clinical grade point of care diagnostics like @tytocare allow virtual exams@CIOStraightTalk #OneHCL #STinsights #clinicaltrials pic.twitter.com/wG6jwUMQFj
That is @TytoCare from Israel, smart medical devices will be the future of #healthcare delivery.
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
Israel has a ton of awesome smart medical device companies! #OneHCL #STinsights #clinicaltrials https://t.co/wM3pb3b5oi
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
Check out @TytoCare's device for looking at a patient's throat remotely! The physician / clinician sees the live video camera feed remotely
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
#OneHCL #STinsights #clinicaltrials pic.twitter.com/U4JmpDNJZs
Remote Patient Monitoring - RPM - supports clinical trials as well
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
Companies like AlacrityCare are using sensors for real-time symptoms and vital signs for oncology patients and clinical trials#OneHCL #STinsights #clinicaltrials #RPMhttps://t.co/8kXxP8yvq3
#STinsights @CIOStraightTalk #OneHCL Agree Robin, traditional RPM models that we've seen through EDC are being enhanced significantly by centralizing the VCT technologies onto such platforms and a direct to patient reach out
— Arifur Deepu (@ArifurDeepu) February 24, 2021
#STinsights we need to totally review our definition of healthcare actually. It should be avoiding sickness and feeling well and nutrition, sport... should be there as our healthcare treatment. Treatment as we see it today would there be a failure of that system.
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Absolutely.
— Arifur Deepu (@ArifurDeepu) February 24, 2021
@Robinff3 💯 I personally am excited that the tech will allow for better data quality (and therefore better insights to safety and efficacy) AND collected in a way that reduces patient burden. Better studies & more convenient - a real win
— Steve Lesser (@lessersteve) February 24, 2021
#STinsights we also need a trusted resources or system to OK that quality. I fear we can easily reproduces the interpretation of the physical world into a digital one. Centralise Vs décentralisation here is the question
— Haider Alleg (@Haider_Alleg) February 24, 2021
That is @TytoCare from Israel, smart medical devices will be the future of #healthcare delivery.
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
A2b: We utilize a vast amount of technology in our daily lives. Combining quality real-time data collection in a passive manner through wearables and sensors will enable an exponential increase in research with a broader and more diverse population @CIOStraightTalk #STInsights
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
I'm glad you brought that up - data quality! Tech is enabling it and patient-centered methodologies are helping increase awareness and adoption. Convenience is key. @CIOStraightTalk #STinsights #OneHC https://t.co/UQ3vHRh0tB
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
Then arises the question of how exactly the industry is making this transition from the traditional to the cutting edge.A2: Technology have a vital role:
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
👉 collecting data
👉 facilitate ongoing patient engagement
👉 managing & diagnosing health conditions
👉 closing the gaps in communications between clinicians & patients
👉 Wearables#pharma #OneHCL #CIOStraightTalk #TheWearablesExpert https://t.co/AH0yhe6aZ1
The bottom line is that moving beyond the traditional is helping a wider, more diverse array of patients unlike ever before.Time for our third question. Keep the questions coming! Join the conversation using #STinsights #Tweetchat #OneHCL pic.twitter.com/2FCplNHnKH
— CIO Straight Talk (@CIOStraightTalk) February 24, 2021
A3a: In Mar/Apr 2020 many patients were unwilling or unable to go on site for a traditional trial visit. Sponsors/CROs began adding televisit capabilities so sites could maintain contact with their patients and capture endpoint data @CIOStraightTalk #STInsights #OneHCL
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#STinsights also being able to filter and triage brought some light to tech that wasn’t that new but showcasing under covid time a huge relevance
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STInsights digital platforms across all industries rose to prominence through covid. This is the future and it's time to embrace it
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
We do need to ensure it's a rising tide that lifts all boats though. We see with digital education during Covid that many poorer children are getting left behind.
— Adi Gaskell (@AdiGaskell) February 24, 2021
The great thing about Virtual Clinical Trials - is that they CAN reach less affluent areas
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
Companies like @Science37x mail a smart tablet to the clinical trial patients instead of assuming the patient has access to a smartphone/tablet@CIOStraightTalk #OneHCL #STinsights
Of course. Just saying that we need to make sure people are aware that the trials exist in the first place. That is likely to require a lo-tech approach as well as a high-tech one, as we're seeing with information campaigns around the vaccine.
— Adi Gaskell (@AdiGaskell) February 24, 2021
#STinsights and get scale quickly
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STinsights we also need to be cooperating. We can’t have one platform per drug anymore it makes no sense. 10 years ago every drug was bundled with a patient support app and if you had 3 treatments to take you had 3 apps to fill in.
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STInsights Excellent point! Something I've thought about a lot. The industry can support device/tech provisioning to even the playing field and improve diversity
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Q3 Key is, Decentralization of Clinical Trials execution framework from the current EDC model by enabling VCT features:
— Arifur Deepu (@ArifurDeepu) February 24, 2021
•Central PI
•Online Patient Recruitment
•eConsent
•Tele-Visit
•biometric real-time measurements
•eDiary
•eCOA
3. Covid has made it crucial to not only operate at breakneck speed but to include a large cross-section of society in trials. Speed and scale are two things virtual trials are really good at @CIOStraightTalk #STinsights #OneHCL
— Adi Gaskell (@AdiGaskell) February 24, 2021
The last year has also highlighted how poor trials are in so many ways. For instance research from @UniofOxford shows how poor they are at generating reliable evidence for treatment usage https://t.co/SDw0YISG0G @CIOStraightTalk #STinsights #OneHCL
— Adi Gaskell (@AdiGaskell) February 24, 2021
A3: #COVID19 has accelerated the approach to VCTs just like with other #digitalhealth. Data collection, processing and insights can occur faster and geographically situated anywhere. @CIOStraightTalk #STinsights #OneHCL #healthdata https://t.co/go2gL4Mq0y
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL agree @Donna and it paving the road for accelerated drug development
— Arifur Deepu (@ArifurDeepu) February 24, 2021
A3:
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
There are always startups, but @Medidata is a 22 yr old SaaS company for clinical trials & they’ve been patient centric for years!
They work w/ most of BigPharma & have an analytics platform for RPM
@CaptainClinical @CIOStraightTalk
#OneHCL #STinsights https://t.co/EMjrotPNzl
Totally agree to this! @DonnaKLencki Will additional regulations be needed to monitor and protect patients as they gain greater access to their health information? #STinsights #OneHCL @ArifurDeepu @WearablesExpert @TheTylerPugsley @IrmaRaste @Robinff3 @Haider_Alleg @AdiGaskell https://t.co/aflXJyjKxC
— Aayu Bajaj (@aayu_bajaj) February 24, 2021
By going virtual, they are able to be more resilient since they're no longer limited to a geographic location w/ a limited patient pool
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
Virtual clinical trials help all of that @CIOStraightTalk #OneHCL #STinsights #Tweetchat
Finally a lot has been demonstrated that the right info, the right service at the right timing is having an impact on our societies. Pharma understands it. Big tech as well: a new race for defining the new healthcare experience is on...
— Haider Alleg (@Haider_Alleg) February 24, 2021
Spot on! Convenience is key and adoption will follow what is seamless with everyday scenarios. @CIOStraightTalk #STinsights #OneHCL #digitalhealth https://t.co/NAG25MqB89
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
#Technology is 🔑 to making #clinicaltrials virtual & distributed! There are many technologies here, from #RPM to #biomarkers to enabling tech like #cloud & #5G. Also new ways of outreach & recruitment. @EvanKirstel @eViRaHealth @CIOStraightTalk #STinsights #OneHCL #digitalhealth https://t.co/psFY8xxMPj
— Irma Rastegayeva✨ Influence Through Storytelling ™ (@IrmaRaste) February 24, 2021
And wearables of course #TheWearablesExpert ⌚️
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
Interesting point @IrmaRaste ! Do you expect a patient’s digital expectations for other parts of healthcare industry to change based on digital experiences in clinical trials? Which process of Healthcare sector do you think would be impacted the most? @TheTylerPugsley#STinsights https://t.co/9K2x5vrlvs
— Apoorva Agarwal (@Apoorva_Ag) February 24, 2021
Interesting point @IrmaRaste ! Do you expect a patient’s digital expectations for other parts of healthcare industry to change based on digital experiences in clinical trials? Which process of Healthcare sector do you think would be impacted the most? @TheTylerPugsley#STinsights https://t.co/9K2x5vrlvs
— Apoorva Agarwal (@Apoorva_Ag) February 24, 2021
Totally agree to this! @DonnaKLencki Will additional regulations be needed to monitor and protect patients as they gain greater access to their health information? #STinsights #OneHCL @ArifurDeepu @WearablesExpert @TheTylerPugsley @IrmaRaste @Robinff3 @Haider_Alleg @AdiGaskell https://t.co/aflXJyjKxC
— Aayu Bajaj (@aayu_bajaj) February 24, 2021
It is almost like Covid created a market and it was super intriguing to see hospitals eating up the market share of that business when they decided to adopt it. Hope for many players in healthcare to leapfrog once we understand exactly what’s working #STinsights
— Haider Alleg (@Haider_Alleg) February 24, 2021
market acceleration !!!!
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
A3: Covid19 has highlighted what we COULD / SHOULD have been doing for quite some time.
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
We are seen now remote monitoring interventions being the " New Normal ". It is not about ONLY about data collection, is about touch points with patients.#STinsights #OneHCL #CIOStraighTalk https://t.co/NnErpaAw0r
100% on patient touch points.
— Michael Dillhyon (@SwissGator) February 24, 2021
The future success of #medtech & #clinicaltrials means a much higher priority & early focus on compliance.
Agreed~ We've spent a lot of time in #healthcare proving #digitalhealth's value. Now, we'll never look back. @CIOStraightTalk #STinsights #OneHCL https://t.co/oVr7MpjfGx
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Couldn't agree more. Covid has exposed what industry should've adopted a long time ago.
— Arifur Deepu (@ArifurDeepu) February 24, 2021
The steps enterprises must take to ensure a successful transition is the next point of focus.#STinsights @CIOStraightTalk #OneHCL sometimes VCT can overburden patients that are participating in trials with various new components. The key is to have complementary patients support infrastructure, including on-demand training support
— Arifur Deepu (@ArifurDeepu) February 24, 2021
Progress can’t be piecemeal, and technology leaders need to step up and make large changes to ensure growth and innovation.A big shoutout to everyone on our panel. Here’s our fourth question. Join the conversation using #STinsights #Tweetchat #OneHCL pic.twitter.com/M7f4YOzGsa
— CIO Straight Talk (@CIOStraightTalk) February 24, 2021
4 As with so much digital transformation, a primary barrier is often a cultural one. Covid has helped to eradicate some of the fears organizations had about virtual trials while also showing regulators both what is possible and what is needed @CIOStraightTalk #STinsights #OneHCL
— Adi Gaskell (@AdiGaskell) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL sometimes VCT can overburden patients that are participating in trials with various new components. The key is to have complementary patients support infrastructure, including on-demand training support
— Arifur Deepu (@ArifurDeepu) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Q4 cont. It has to be in the likes of how we’ve seen the EDC implementation across the industry about 15/20 years ago. VCT implementation needs to be treated as a large-scale Digital Transformation program – under the corporate CDO office
— Arifur Deepu (@ArifurDeepu) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Q4 cont. Key ingredients for an enterprise scale VCT impl for a pharma requires an integrated offering:
— Arifur Deepu (@ArifurDeepu) February 24, 2021
•established Med Dev/SaMD capabilities
•Robust VCT Platform
•Asset Provisioning with global reach
•Multilingual Support & Training
For obvious biz disruption reasons...enterprise #Pharma tends to strongly resist wholesale IT “platform” transitions...consider a value-added layered VCT approach to augment legacy systems @Medidata
— Michael Dillhyon (@SwissGator) February 24, 2021
#Technology is crucial to reducing the overburden on patients. #Wearables are great but still require active patient participation. We need more #passive monitoring solutions that use #IoT to collect data from patients without requiring them to complete tasks, etc. #STinsights https://t.co/6234AVfkvG
— Ashley A. Holmes (@AshleyAHolmes1) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Q4 Current VCT adoption model is study specific as the demand dictates. To realize the full benefit of VCT across a company’s clinical portfolio, the implementation model needs to be initiated at the corp level with Clinical & IT partnership
— Arifur Deepu (@ArifurDeepu) February 24, 2021
#STinsights a bit connected to the company culture first. It can’t be someone’s project for 2 years... it truly needs to be anchored in the DNA of a data driven company
— Haider Alleg (@Haider_Alleg) February 24, 2021
A4a: By integrating FLEXIBLE VCT/DCT solutions into an org’s infrastructure and processes so VCT is optimized for efficient data & workflows for any use case. Fully embedded aspects of VCT/DCT can easily be added when it benefits a study @CIOStraightTalk #STInsights #OneHCL
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#STinsights it also need to be seen as a company effort not just a nice pilot. I can see it too often presented as a nice to have like: we could do that as well...) this shows to me that we@often don’t understand the true potential of it even when we try it.
— Haider Alleg (@Haider_Alleg) February 24, 2021
I do not see the "pilot" approach as problematic. Having an opportunity to deploy & show results as a way to move forward with the industry might be OK, esp in the more concervative world of #pharma @BavassoRichie @Seqster @akalali @drecroach @Gil_Bashe #STinsights #DigitalHealth
— Irma Rastegayeva✨ Influence Through Storytelling ™ (@IrmaRaste) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL I Agree Irma. Pilots were essential but the industry is now ready to adopt full capabilities of VCT
— Arifur Deepu (@ArifurDeepu) February 24, 2021
Data driven approach is key 💯
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
And crazy enough when you approach this topic people think is all about tech but no this is culture and decision making. The role of leaders showing a path here is crucial.
— Haider Alleg (@Haider_Alleg) March 5, 2021
True if you have a plan to scale beyond pilots... which is where it hurts
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STInsights personally I've witnessed a dramatic shift in perception from nice to have to must have. Edge case to main case. The forced adoption through covid has led to greater acceptance through trial and error
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#STinsights I agree it is going the right way but then it is not a tech issue or an ecosystem issue but a people issue as we are waiting for a crisis to adapt. That’s why for me to do credits to the topic we need to really be clear on the outcomes and the gain
— Haider Alleg (@Haider_Alleg) February 24, 2021
Workflow automation is another area. It can improve clinical trial productivity, provides insights from large volumes of #healthdata generated from clinical trials, #EHRs, claims, etc. @CIOStraightTalk #STinsights #OneHC #digitalhealth
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
A4b: Once an ecosystem is built, individual studies can be designed to reap the VCT benefits for patients and sponsors. @CIOStraightTalk #STInsights #OneHCL
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#STinsights very good point. If we had the App Store equivalent of VCT then people would want to have their app in it. Oh wait, you already have it Tyler ;)
— Haider Alleg (@Haider_Alleg) February 24, 2021
Agree, the "ecosystem" and market acceptance are key to wide adoption of virtual #clinicaltrials! But how we get there is still to be seen. Let's not underestimate the grass roots #patient efforts in pushing for more #equity & access. @GraceCordovano @stacy_hurt #STinsights
— Irma Rastegayeva✨ Influence Through Storytelling ™ (@IrmaRaste) February 24, 2021
A4: well first, I would be thinking about would not be Technology.
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
I would take time to strategically consider all the necessary elements, people, culture, change management, education and construct a project in his own right, THEN lay the technology on it. #STinsights #OneHCL https://t.co/8ZZXvMTHTB
Yes! Plan for and incorporate #digitalhealth technologies into study design at the forefront – mobile apps, devices, remote monitoring and online social engagement. @CIOStraightTalk #STinsights #OneHC
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
And finally, the panel considers the long-term consequences digital will have on clinical trials as whole.It's critical to carefully consider elements at the beginning to ensure health technologies used to enhance monitoring and improve understanding of treatment effects and disease progression. @CIOStraightTalk #STinsights #OneHC #clinicaltrials https://t.co/LYVfvHq4PT
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
Technology will broaden the reach of clinical trials and ensure critical solutions are discovered faster and will greater access to all.Here’s our final formal question to the panel. Keep shooting YOUR questions using #STinsights #OneHCL #Tweetchat pic.twitter.com/UYGcuNUMAM
— CIO Straight Talk (@CIOStraightTalk) February 24, 2021
5 Virtual clinical trials promise to improve patient recruitment, engagement, retention, and data collection, while also supporting shorter trial duration and therefore lower costs. If we're to achieve precision medicine, this will be crucial @CIOStraightTalk #STinsights #OneHCL
— Adi Gaskell (@AdiGaskell) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Here’s a sample of how HCL is helping its customers implement Enterprise Scale (across TAs) VCT setups with a comprehensive offering pic.twitter.com/AKyGmpDBBQ
— Arifur Deepu (@ArifurDeepu) February 24, 2021
A5:
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
Many clinical trials fail due to patient recruitment & drop out.
Bc remote trials are easier for the patient, there will be less drop-outs.
#OneHCL #STinsights #Tweetchat pic.twitter.com/bYbXPHh6Vz
Check out these numbers
— Robin Farmanfarmaian (@Robinff3) February 24, 2021
Up to 50% of clinical trials aren't filled
Virtual #clinicaltrials can change that #OneHCL #STinsights #Tweetchat pic.twitter.com/3fvYGcnoDE
remote is " the " word, and wearables are the vehicle.
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
Well said!
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
Thanks Donna
— João Bocas, The Wearables Expert ™⌚️#digitalhealth (@WearablesExpert) February 24, 2021
VCTs have high recruitment rates, better compliance, lower drop-out rates and conducted faster than conventional trials. Low risk and high return and ability to bring a new treatment to patients faster. @CIOStraightTalk #STinsights #OneHC https://t.co/TGeTwjgwjh
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
They've got to be a big part of the mix, haven't they?
— Adi Gaskell (@AdiGaskell) February 24, 2021
A4: Leverage #digitalhealth for collecting info at each stage of clinical trial — the design needs to enable online-based informed consent, measurement in real-time at clinical endpoints and use #AI to continuously track/address adverse events. @CIOStraightTalk #STinsights #OneHC https://t.co/ab1joEvXyl
— Donna K. Lencki (@DonnaKLencki) February 24, 2021
#digitalhealth provides the ability for real-time, real-world data to be collected as part of #clinicaltrials. This is a huge improvement from having a small number of discrete touchpoints with a patient during a trial. #STinsights #OneHC https://t.co/eBdAQIZBlo
— Ashley A. Holmes (@AshleyAHolmes1) February 24, 2021
It will also be interesting to see just how clinical trials look after Covid has exposed the amount of wastage involved @CIOStraightTalk #STinsights #OneHCL
— Adi Gaskell (@AdiGaskell) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Q5 VCTs are conducted having patient centricity in mind. It helps with
— Arifur Deepu (@ArifurDeepu) February 24, 2021
•broadening patient access
•reduce burden of trial participants
•on-time Data collection & safety monitoring
•Improve trial Adherence
•On time Trial Completion
A5a: A recent study by Greenphire Data showed 84% of sponsors & CROs are actively seeking technology to better support DCT. Network effects and ROI will continue it's increased adoption for drug development @CIOStraightTalk #STInsights #OneHCL
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#STinsights CROs are an important player here as they can also determine the way this goes for the ecosystem. If they educate the market then it will naturally enter processes. Again, too much pitched as a nice slide bundled with AI, ML DL and people put VCT in a black box
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STInsights CROs are adapting and embracing DCT through technology partnerships and acquisitions. I'm optimistic this trend will continue and accelerate
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
#STinsights many possibilities as we have to be faster, for new drugs, new labels and potentially now drugs + DTx you can plan better and reach a scale that was not possible years ago
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL yes, but the industry wide implementation of VCT will not materialize if industry mindset does not change about how fundamental the adoption of VCT is post Covid era
— Arifur Deepu (@ArifurDeepu) February 24, 2021
Let's break it down to the core objective: Speed to safe and effective drug approvals. #STInsights #OneHCL
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
These are powerful statistics. Virtual #clinicaltrials are by nature much more #patientcentric as they are more inclusive of ALL patients, not just those have the means, time, and willingness to travel & contribute to clinical trials. #STinsights #OneHCL https://t.co/YEUCpevcmF
— Ashley A. Holmes (@AshleyAHolmes1) February 24, 2021
And with that, we offer up our thanks to the panel for a truly illuminating discussion. We will see you back here very soon!A5b: With VCT/DCT, trials will be more diverse, faster, and more cost effective. All stakeholders benefit. Read here: https://t.co/EyOvUzVfIJ @CIOStraightTalk #STInsights #OneHCL
— Tyler Pugsley (@TheTylerPugsley) February 24, 2021
A big thank you to our Power Panel for their #STinsights and those who joined us for this exclusive discussion on our #Tweetchat #OneHCL @ArifurDeepu @TheTylerPugsley @DonnaKLencki @IrmaRaste @Haider_Alleg @Robinff3 @WearablesExpert @AdiGaskell pic.twitter.com/bZDz3txQ75
— CIO Straight Talk (@CIOStraightTalk) February 24, 2021
Was a pleasure thanks for hosting and thanks for all the others panelist #STinsights
— Haider Alleg (@Haider_Alleg) February 24, 2021
#STinsights @CIOStraightTalk #OneHCL Many thanks for this very informative and interective session @CIOStraightTalk for inviting me & to my fellow panelists @ArifurDeepu @TheTylerPugsley @DonnaKLencki @Haider_Alleg @Robinff3 @WearablesExpert @AdiGaskell & all participants
— Arifur Deepu (@ArifurDeepu) February 24, 2021
Great chat! Thank you @CIOStraightTalk for inviting me & to my fellow panelists @ArifurDeepu @TheTylerPugsley @DonnaKLencki @Haider_Alleg @Robinff3 @WearablesExpert @AdiGaskell & all participants 🙏#STinsights #ClinicalTrials #DigitalHealth #HealthTech #pharma #healthcare #RPM https://t.co/OpmqQ61BRY
— Irma Rastegayeva✨ Influence Through Storytelling ™ (@IrmaRaste) February 24, 2021